Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-09-30, Stock:ABBV, The news for the past five days is as follows:
2021-09-23: NEWS1: AbbVie Presents New Data Analyses for Growing Dermatology Portfolio at the 30th European Academy of Dermatology and Venereology (EADV) Congress.NEWS2: 3 Relatively Safe Pharma Stocks You Can Buy Right Now.
2021-09-24: NEWS1: Takeda Guilty Of Supply Contract Breach With AbbVie For Prostate Cancer Drug.NEWS2: AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?.NEWS3: Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot.
2021-09-27: NEWS1: AbbVie (ABBV) Gains As Market Dips: What You Should Know.NEWS2: Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals.NEWS3: Could AbbVie's New Collaboration Be a Blockbuster?.NEWS4: 3 High-Yield Dividend Stocks Warren Buffett Loves.
2021-09-28: NEWS1: UPDATE 1-U.S. FDA approves AbbVie's migraine prevention drug.NEWS2: FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine.NEWS3: 3 Top Stocks for Retirees.
2021-09-29: NEWS1: AbbVie's (ABBV) Migraine Prevention Drug Qulipta Gets FDA Nod.NEWS2: Here's How a New Investor Started Her Portfolio With Just 10 Top Stocks.NEWS3: FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie.NEWS4: The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug.NEWS5: Here's Why AbbVie Is a Great Healthcare Stock for Long-Term Investors.

Answer: Decrease